Current Report Filing (8-k)
April 20 2021 - 8:31AM
Edgar (US Regulatory)
0001551152
false
Common Stock, $0.01 Par Value
ABBV
0001551152
2021-04-16
2021-04-16
0001551152
us-gaap:CommonStockMember
exch:XNYS
2021-04-16
2021-04-16
0001551152
exch:XCHI
us-gaap:CommonStockMember
2021-04-16
2021-04-16
0001551152
abbv:SeniorNotes0.500Percentdue2021Member
exch:XNYS
2021-04-16
2021-04-16
0001551152
abbv:SeniorNotes1.500Percentdue2023Member
exch:XNYS
2021-04-16
2021-04-16
0001551152
abbv:SeniorNotes1.375Percentdue2024Member
exch:XNYS
2021-04-16
2021-04-16
0001551152
abbv:SeniorNotes1.250Percentdue2024Member
exch:XNYS
2021-04-16
2021-04-16
0001551152
abbv:SeniorNotes0.750Percentdue2027Member
exch:XNYS
2021-04-16
2021-04-16
0001551152
abbv:SeniorNotes2.125Percentdue2028Member
exch:XNYS
2021-04-16
2021-04-16
0001551152
abbv:SeniorNotes2.625Percentdue2028Member
exch:XNYS
2021-04-16
2021-04-16
0001551152
abbv:SeniorNotes2.125Percentdue2029Member
exch:XNYS
2021-04-16
2021-04-16
0001551152
abbv:SeniorNotes1.250Percentdue2031Member
exch:XNYS
2021-04-16
2021-04-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): April 16, 2021
ABBVIE INC.
(Exact Name of Registrant as Specified
in its Charter)
_______________________________________________
Delaware
|
|
|
|
32-0375147
|
(State or other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
_______________________________________________
1 North Waukegan Road
North Chicago, Illinois 60064-6400
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including
area code: (847) 932-7900
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered
pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which
registered
|
Common Stock, $0.01 Par Value
|
|
ABBV
|
|
New York Stock Exchange
Chicago Stock Exchange
|
0.500% Senior Notes due 2021
|
|
ABBV21C
|
|
New York Stock Exchange
|
1.500% Senior Notes due 2023
|
|
ABBV23B
|
|
New York Stock Exchange
|
1.375% Senior Notes due 2024
|
|
ABBV24
|
|
New York Stock Exchange
|
1.250% Senior Notes due 2024
|
|
ABBV24B
|
|
New York Stock Exchange
|
0.750% Senior Notes due 2027
|
|
ABBV27
|
|
New York Stock Exchange
|
2.125% Senior Notes due 2028
|
|
ABBV28
|
|
New York Stock Exchange
|
2.625% Senior Notes due 2028
|
|
ABBV28B
|
|
New York Stock Exchange
|
2.125% Senior Notes due 2029
|
|
ABBV29
|
|
New York Stock Exchange
|
1.250% Senior Notes due 2031
|
|
ABBV31
|
|
New York Stock Exchange
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01
|
Regulation FD Disclosure.
|
On April 16, 2021, AbbVie Inc. delivered a
notice of redemption to the holders of its 0.500% Senior Notes due 2021 (the “Notes”), announcing the redemption on May 1,
2021 of all of its outstanding Notes. A copy of the notice is attached as Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated herein in its entirety.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ABBVIE INC.
|
|
|
Date:
April 20, 2021
|
By:
|
/s/ Robert A. Michael
|
|
Name: Robert
A. Michael
|
|
Title: Executive
Vice President, Chief Financial Officer
|
Common Stock, $0.01 Par Value
|
ABBV
|
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2024 to Jul 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jul 2023 to Jul 2024